Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMO 2055

Drug Profile

IMO 2055

Alternative Names: EMD 1201081; HYB-2055; IMO-2055; IMOxine; TLR9 immunomodulator

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; Merck KGaA
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer; Head and neck cancer; Non-small cell lung cancer

Highest Development Phases

  • Suspended Colorectal cancer; Non-small cell lung cancer
  • No development reported Cancer; Head and neck cancer
  • Discontinued Asthma; Renal cell carcinoma

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural, Injection)
  • 04 Aug 2015 No recent reports on development identified - Phase-II for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA, Belgium, Czech Republic, France, Hungary, United Kingdom, Slovakia and Poland (SC)
  • 02 Dec 2014 Final pharmacodynamics data from preclinical models of bladder, colon, and lung cancer released by Idera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top